Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled KB407 Phase I Study in Cystic Fibrosis
NCT05095246Phase 1Withdrawn
- Sponsor
- Krystal Biotech, Inc.
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of KB407 in cystic fibrosis (CF) (3 cohorts), sponsored by Krystal Biotech, Inc. Primary endpoint: Safety and Tolerability (Adverse Events) at 60 days. Planned start Mar 2022; status: withdrawn.
02
Drugs
KB407
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05095246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095246.